{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:34:36Z","timestamp":1781076876651,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03651-w","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T18:01:51Z","timestamp":1723744911000},"page":"1211-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7179-0906","authenticated-orcid":false,"given":"C\u00e9sar","family":"Guti\u00e9rrez P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Lastra Aras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Saiz L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Garc\u00eda Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Blanco Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodr\u00edguez Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Pumares Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Vela Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Espinosa Cabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Crespo Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"3651_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s12094-022-02815-w","volume":"24","author":"BP Valderrama","year":"2022","unstructured":"Valderrama BP, Gonz\u00e1lez-Del-Alba A, Morales-Barrera R, Fern\u00e1ndez IP, V\u00e1zquez S, D\u00edaz CC, et al. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol. 2022;24:613\u201324. https:\/\/doi.org\/10.1007\/s12094-022-02815-w.","journal-title":"Clin Transl Oncol"},{"key":"3651_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3651_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"3651_CR4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol. 2019;30:970\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdz127.","journal-title":"Ann Oncol"},{"key":"3651_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"3651_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/s1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(21)00094-2.","journal-title":"Lancet Oncol"},{"key":"3651_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"key":"3651_CR8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"key":"3651_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, \u00d6zg\u00fcro\u011flu M, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35:107\u201317. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.003.","journal-title":"Ann Oncol"},{"key":"3651_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"key":"3651_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895\u2013902. https:\/\/doi.org\/10.1093\/annonc\/mdy263.","journal-title":"Ann Oncol"},{"key":"3651_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","volume":"80","author":"MS van der Heijden","year":"2021","unstructured":"van der Heijden MS, Loriot Y, Dur\u00e1n I, Ravaud A, Retz M, Vogelzang NJ, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial. Eur Urol. 2021;80:7\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.024.","journal-title":"Eur Urol"},{"key":"3651_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.cd-17-0151","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","unstructured":"AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0151.","journal-title":"Cancer Discov"},{"key":"3651_CR14","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3892\/ol.2017.6621","volume":"14","author":"HW Kang","year":"2017","unstructured":"Kang HW, Kim YH, Jeong P, Park C, Kim WT, Ryu DH, et al. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett. 2017;14:3817\u201324. https:\/\/doi.org\/10.3892\/ol.2017.6621.","journal-title":"Oncol Lett"},{"key":"3651_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100641","volume":"7","author":"K Murugesan","year":"2022","unstructured":"Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, et al. Pan-tumor landscape of fibroblast growth factor receptor 1\u20134 genomic alterations. ESMO Open. 2022;7: 100641. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100641.","journal-title":"ESMO Open"},{"key":"3651_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med"},{"key":"3651_CR17","doi-asserted-by":"publisher","first-page":"12659","DOI":"10.3390\/ijms232012659","volume":"23","author":"V Albarr\u00e1n","year":"2022","unstructured":"Albarr\u00e1n V, Rosero DI, Chamorro J, Pozas J, Rom\u00e1n MS, Barrill AM, et al. Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates. Int J Mol Sci. 2022;23:12659. https:\/\/doi.org\/10.3390\/ijms232012659.","journal-title":"Int J Mol Sci"},{"key":"3651_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189\u201394. https:\/\/doi.org\/10.1038\/nature25475.","journal-title":"Nature"},{"key":"3651_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","volume":"47","author":"J Zhao","year":"2015","unstructured":"Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47:87\u201394. https:\/\/doi.org\/10.1007\/s11255-014-0866-z.","journal-title":"Int Urol Nephrol"},{"key":"3651_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/jco.22.02636","volume":"42","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors. J Clin Oncol. 2024;42:258\u201365. https:\/\/doi.org\/10.1200\/jco.22.02636.","journal-title":"J Clin Oncol"},{"key":"3651_CR21","doi-asserted-by":"publisher","first-page":"12071","DOI":"10.1002\/cam4.5893","volume":"12","author":"EGE de Vries","year":"2023","unstructured":"de Vries EGE, R\u00fcschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma. Cancer Med. 2023;12:12071\u201383. https:\/\/doi.org\/10.1002\/cam4.5893.","journal-title":"Cancer Med"},{"key":"3651_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/jco.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358. https:\/\/doi.org\/10.1200\/jco.23.02005.","journal-title":"J Clin Oncol"},{"key":"3651_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.536072","volume":"10","author":"Z Wang","year":"2020","unstructured":"Wang Z, Shang J, Li Z, Li H, Zhang C, He K, et al. PIK3CA is regulated by CUX1, promotes cell growth and metastasis in bladder cancer via activating epithelial\u2013mesenchymal transition. Front Oncol. 2020;10: 536072. https:\/\/doi.org\/10.3389\/fonc.2020.536072.","journal-title":"Front Oncol"},{"key":"3651_CR24","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1002\/cncr.33071","volume":"126","author":"V McPherson","year":"2020","unstructured":"McPherson V, Reardon B, Bhayankara A, Scott SN, Boyd ME, Garcia-Grossman IR, et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. 2020;126:4532\u201344. https:\/\/doi.org\/10.1002\/cncr.33071.","journal-title":"Cancer"},{"key":"3651_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clgc.2023.07.009","volume":"21","author":"T Gamba","year":"2023","unstructured":"Gamba T, Paparo J, Panepinto O, Dionisio R, di Maio M, Vignani F. Poly (ADP-Ribose) polymerase inhibitors in patients with urothelial cancer. Clin Genitourin Cancer. 2023;21:509\u201316. https:\/\/doi.org\/10.1016\/j.clgc.2023.07.009.","journal-title":"Clin Genitourin Cancer"},{"key":"3651_CR26","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1158\/1078-0432.ccr-20-1246","volume":"26","author":"HW Lee","year":"2020","unstructured":"Lee HW, Sa JK, Gualberto A, Scholz C, Sung HH, Jeong BC, et al. A phase II trial of tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations. Clin Cancer Res. 2020;26:5113\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-1246.","journal-title":"Clin Cancer Res"},{"key":"3651_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","volume":"34","author":"J Ros","year":"2023","unstructured":"Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023;34:543\u201352. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.016.","journal-title":"Ann Oncol"},{"key":"3651_CR28","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3389\/fimmu.2020.01620","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Huang Y, Gao X, Li Y, Lin J, Chen L, et al. CCND1 amplification contributes to immunosuppression and is associated with a poor prognosis to immune checkpoint inhibitors in solid tumors. Front Immunol. 2020;11:1620. https:\/\/doi.org\/10.3389\/fimmu.2020.01620.","journal-title":"Front Immunol"},{"key":"3651_CR29","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.3390\/cancers14246174","volume":"14","author":"MK Kilroy","year":"2022","unstructured":"Kilroy MK, Park S, Feroz W, Patel H, Mishra R, Alanazi S, et al. HER3 alterations in cancer and potential clinical implications. Cancers (Basel). 2022;14:6174. https:\/\/doi.org\/10.3390\/cancers14246174.","journal-title":"Cancers (Basel)"},{"key":"3651_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4143\/crt.2019.062","volume":"52","author":"JM Bae","year":"2020","unstructured":"Bae JM, Wen X, Kim TS, Kwak Y, Cho NY, Lee HS, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification detected by droplet digital polymerase chain reaction (ddPCR) is a prognostic factor in colorectal cancers. Cancer Res Treat. 2020;52:74\u201384. https:\/\/doi.org\/10.4143\/crt.2019.062.","journal-title":"Cancer Res Treat"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03651-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:42:33Z","timestamp":1742190153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03651-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03651-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved and authorized by the Ethics Committee of the Hospital Universitario de Burgos.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed consent for genomic studies and data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}